Subcutaneous Abatacept Versus Intravenous Abatacept: A Phase IIIb Noninferiority Study in Patients With an Inadequate Response to Methotrexate
Genovese MC, Covarrubias A, Leon G, et al
Arthritis Rheum. 2011;63:2854-2864
Background
Abatacept has been approved for the treatment of moderate to severe rheumatoid arthritis (RA) as an intravenous (IV) infusion, and more recently as a subcutaneous (SC) infusion, with or without concomitant methotrexate. However, IV infusions may be problematic for some patients in terms of access to infusion centers or time spent receiving infusions. Genovese and coworkers reported the results of a large-scale international trial comparing the efficacy and safety of SC vs IV abatacept.